OnSource Corporation has changed its name to Ceragenix Pharmaceuticals, Inc. The change in name follows the merger of OnSource with Osmotics Pharma, Inc. on May 11, 2005, and reflects the combined company’s revised business strategy and commitment to delivering innovative products for dermatology and infectious disease.
“This important step acknowledges our strategic decision to launch a new biopharmaceutical company around our two platform technologies,” commented Steven Porter, Chairman and CEO of Ceragenix. “This is a very exciting time for our organization as we move forward into the initial commercialization of our medical devices, including the upcoming anticipated 510k filing for EpiCeram(tm), the first topical formulation of our barrier repair technology, and the further development of our unique Cationic Steroid Antibiotic Technology for potentially long-lasting antimicrobial medical device coatings. We are thrilled to be moving forward under the name Ceragenix Pharmaceuticals.”
In conjunction with this name change, Ceragenix Pharmaceuticals will now be quoted on the OTC Bulletin Board under the symbol CGXP.
